US Patent Issued to LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY on Oct. 21 for "Human ApoB100 epitopes, methods and uses for modulating inflammatory responses, and treating adverse cardiovascular events, disease and atherosclerosis" (California Inventors)

ALEXANDRIA, Va., Oct. 28 -- United States Patent no. 12,448,433, issued on Oct. 21, was assigned to LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (La Jolla, Calif.).

"Human ApoB100 epitopes, methods and uses for modulating inflammatory responses, and treating adverse cardiovascular events, disease and atherosclerosis" was invented by Klaus Ley (La Jolla, Calif.) and Alessandro Sette (La Jolla, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are composition comprising novel epitopes of ApoB100, as well as sub-sequences, portions and modifications thereof, and uses thereof for treating adverse cardiovascular events, cardiovascular disease, atherosclerosis and certain liver disorders."

Th...